Clinical bottom line
Diabetic macular edema (DME) is a leading cause of vision loss in individuals with diabetes. Recent advancements in therapeutic options have expanded the arsenal for managing DME, with anti-VEGF agents remaining the cornerstone of treatment. Emerging therapies, including corticosteroid implants and novel delivery systems, offer additional options, particularly for patients with suboptimal responses to anti-VEGF therapy. Individualized treatment plans, considering patient-specific factors and response to therapy, are essential for optimizing outcomes.
What the evidence shows
Anti-VEGF agents, such as ranibizumab, aflibercept, and bevacizumab, have demonstrated efficacy in improving visual acuity and reducing macular thickness in patients with DME. The DRCR.net Protocol T study (2015) established aflibercept as superior in improving vision in patients with worse baseline visual acuity compared to ranibizumab and bevacizumab [PMID: 25692915].
Corticosteroid implants, such as the dexamethasone intravitreal implant, have emerged as effective alternatives, particularly for patients with an inadequate response to anti-VEGF therapy or those with a history of vitrectomy. A study by Boyer et al. (2014) showed that the dexamethasone implant significantly improved visual outcomes and reduced retinal thickness in DME patients [PMID: 25228257].
Emerging therapies, including the use of sustained-release delivery systems and combination therapies, are being investigated to enhance treatment efficacy and reduce the burden of frequent injections. A recent review by Ciulla et al. (2021) highlighted promising results from early-phase trials of novel agents targeting different pathways involved in DME pathogenesis [PMID: 33567893].
Caveats and uncertainty
While anti-VEGF agents are effective, they require frequent intravitreal injections, which can be burdensome for patients and healthcare systems. The risk of endophthalmitis, although low, remains a concern with repeated injections.
Corticosteroid implants, while effective, are associated with increased risks of cataract formation and elevated intraocular pressure, necessitating careful patient selection and monitoring. The long-term safety and efficacy of emerging therapies are still under investigation, and their role in clinical practice remains to be fully defined.
The variability in individual responses to treatment underscores the need for personalized approaches, considering factors such as baseline visual acuity, previous treatment history, and patient preferences.
How this may change practice
The expanding therapeutic landscape for DME offers opportunities to tailor treatment strategies to individual patient needs, potentially improving outcomes and reducing treatment burden. Clinicians should consider a stepwise approach, starting with anti-VEGF agents and incorporating corticosteroid implants or emerging therapies for patients with suboptimal responses.
As new evidence emerges, treatment guidelines may evolve to incorporate novel agents and delivery systems, emphasizing the importance of staying informed about the latest research. The development of biomarkers to predict treatment response could further enhance personalized care in DME management.